Sab Biotherapeutics Inc (SABS)

$2.62

+0.16

(+6.51%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $2.50
    $2.66
    $2.62
    downward going graph

    4.58%

    Downside

    Day's Volatility :6.02%

    Upside

    1.5%

    downward going graph
  • $0.95
    $10.50
    $2.62
    downward going graph

    63.74%

    Downside

    52 Weeks Volatility :90.95%

    Upside

    75.05%

    downward going graph

Returns

PeriodSab Biotherapeutics IncIndex (Russel 2000)
3 Months
-14.29%
0.0%
6 Months
-44.34%
0.0%
1 Year
-65.29%
0.0%
3 Years
-96.63%
-20.2%

Highlights

Market Capitalization
27.7M
Book Value
$5.0
Earnings Per Share (EPS)
-6.16
Wall Street Target Price
12.75
Profit Margin
0.0%
Operating Margin TTM
-3876.95%
Return On Assets TTM
-58.8%
Return On Equity TTM
-122.49%
Revenue TTM
2.8M
Revenue Per Share TTM
0.37
Quarterly Revenue Growth YOY
207.7%
Gross Profit TTM
-12.5M
EBITDA
-40.9M
Diluted Eps TTM
-6.16
Quarterly Earnings Growth YOY
-0.6
EPS Estimate Current Year
-3.55
EPS Estimate Next Year
-2.76
EPS Estimate Current Quarter
-1.13
EPS Estimate Next Quarter
-1.16

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Sab Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 386.64%

Current $2.62
Target $12.75

Company Financials

FY19Y/Y Change
Revenue
3.4M
-
Net Income
-9.4M
-
Net Profit Margin
-273.62%
-
FY20Y/Y Change
Revenue
55.2M
↑ 1504.91%
Net Income
20.1M
↓ 313.62%
Net Profit Margin
36.42%
↑ 310.04%
FY21Y/Y Change
Revenue
60.9M
↑ 10.21%
Net Income
-17.4M
↓ 186.71%
Net Profit Margin
-28.66%
↓ 65.08%
FY22Y/Y Change
Revenue
23.9M
↓ 60.73%
Net Income
-18.7M
↑ 7.43%
Net Profit Margin
-78.4%
↓ 49.74%
FY23Y/Y Change
Revenue
2.2M
↓ 90.63%
Net Income
-42.2M
↑ 125.14%
Net Profit Margin
-1.9K%
↓ 1806.1%
Q1 FY23Q/Q Change
Revenue
2.2M
-
Net Income
-7.9M
↑ 0.0%
Net Profit Margin
-364.42%
-
Q2 FY23Q/Q Change
Revenue
85.5K
↓ 96.04%
Net Income
-6.9M
↓ 12.62%
Net Profit Margin
-8.0K%
↓ 7681.71%
Q3 FY23Q/Q Change
Revenue
1.3M
↑ 1381.98%
Net Income
-5.1M
↓ 25.85%
Net Profit Margin
-402.59%
↑ 7643.54%
Q4 FY23Q/Q Change
Revenue
305.0K
↓ 75.93%
Net Income
-22.9M
↑ 347.97%
Net Profit Margin
-7.5K%
↓ 7091.16%
Q1 FY24Q/Q Change
Revenue
944.6K
↑ 209.69%
Net Income
-5.0M
↓ 78.01%
Net Profit Margin
-532.06%
↑ 6961.69%
Q2 FY24Q/Q Change
Revenue
263.1K
↓ 72.14%
Net Income
-7.3M
↑ 45.96%
Net Profit Margin
-2.8K%
↓ 2255.63%
FY19Y/Y Change
Total Assets
18.0M
-
Total Liabilities
20.3M
-
FY20Y/Y Change
Total Assets
56.5M
↑ 214.04%
Total Liabilities
17.5M
↓ 13.68%
FY21Y/Y Change
Total Assets
79.4M
↑ 40.38%
Total Liabilities
40.8M
↑ 132.85%
FY22Y/Y Change
Total Assets
50.9M
↓ 35.86%
Total Liabilities
19.8M
↓ 51.38%
FY23Y/Y Change
Total Assets
83.9M
↑ 64.9%
Total Liabilities
26.6M
↑ 34.24%
Q1 FY23Q/Q Change
Total Assets
50.9M
↑ 0.0%
Total Liabilities
19.8M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
35.4M
↓ 30.37%
Total Liabilities
15.7M
↓ 20.76%
Q3 FY23Q/Q Change
Total Assets
28.3M
↓ 20.05%
Total Liabilities
13.1M
↓ 16.82%
Q4 FY23Q/Q Change
Total Assets
83.9M
↑ 196.23%
Total Liabilities
26.6M
↑ 103.68%
Q1 FY24Q/Q Change
Total Assets
71.4M
↓ 14.97%
Total Liabilities
18.5M
↓ 30.37%
Q2 FY24Q/Q Change
Total Assets
61.9M
↓ 13.28%
Total Liabilities
15.8M
↓ 14.97%
FY19Y/Y Change
Operating Cash Flow
-9.2M
-
Investing Cash Flow
-608.7K
-
Financing Cash Flow
3.7M
-
FY20Y/Y Change
Operating Cash Flow
10.0M
↓ 208.58%
Investing Cash Flow
-12.7M
↑ 1989.98%
Financing Cash Flow
9.0M
↑ 143.98%
FY21Y/Y Change
Operating Cash Flow
3.8M
↓ 62.43%
Investing Cash Flow
-10.9M
↓ 13.98%
Financing Cash Flow
34.1M
↑ 279.85%
FY22Y/Y Change
Operating Cash Flow
3.8M
↑ 0.0%
Investing Cash Flow
-2.1M
↓ 80.9%
Financing Cash Flow
34.1M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
27.4M
↑ 12558.99%
Investing Cash Flow
105.2M
↓ 89444.18%
Financing Cash Flow
39.7M
↑ 499.84%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.9M
↓ 117.86%
Investing Cash Flow
-22.7K
↓ 100.02%
Financing Cash Flow
-363.8K
↓ 100.92%

Technicals Summary

Sell

Neutral

Buy

Sab Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sab Biotherapeutics Inc
Sab Biotherapeutics Inc
-12.77%
-44.34%
-65.29%
-96.63%
-96.63%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-13.97%
8.28%
24.49%
82.67%
258.6%
Novo Nordisk A/s
Novo Nordisk A/s
-14.46%
-7.16%
29.25%
137.43%
348.48%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
77.93%
59.32%
38.21%
249.95%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
12.26%
28.5%
155.67%
163.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sab Biotherapeutics Inc
Sab Biotherapeutics Inc
NA
NA
NA
-3.55
-1.22
-0.59
NA
5.0
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sab Biotherapeutics Inc
Sab Biotherapeutics Inc
Buy
$27.7M
-96.63%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
258.6%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
348.48%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
249.95%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.05%
32.84
-4.74%

Insights on Sab Biotherapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 944.57K → 263.13K (in $), with an average decrease of 72.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -5.02M → -7.33M (in $), with an average decrease of 46.0% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 124.6%

Institutional Holdings

  • Bvf Inc

    9.94%

  • RTW INVESTMENTS, LLC

    8.31%

  • Marshall Wace Asset Management Ltd

    4.98%

  • Sessa Capital IM LP

    4.97%

  • Vanguard Group Inc

    2.99%

  • Geode Capital Management, LLC

    0.64%

Company Information

sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.

Organization
Sab Biotherapeutics Inc
Employees
57
CEO
Mr. Samuel J. Reich
Industry
Miscellaneous

Discover More

FAQs